Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The C4 Therapeutics, Inc. (CCCC) SEC filings page on Stock Titan provides structured access to the companys regulatory disclosures as filed with the U.S. Securities and Exchange Commission. C4 Therapeutics is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detail on clinical progress, collaborations, financings and corporate governance related to its targeted protein degradation programs.
Investors can use this page to review Form 8-K current reports in which C4 Therapeutics furnishes quarterly financial results, business highlights and updates on key clinical programs such as cemsidomide, an investigational IKZF1/3 degrader in development for relapsed/refractory multiple myeloma and non-Hodgkins lymphoma. 8-K filings also document material events including the clinical trial collaboration and supply agreement with Pfizer for elranatamab, underwritten equity offerings involving common stock and warrants, and stockholder approvals to increase authorized shares.
In addition to event-driven 8-Ks, the companys shelf registration statements, prospectus supplements and related exhibits describe the terms of securities offerings used to fund its pipeline, including cemsidomide, CFT8919 and other degrader programs. Governance-related filings, such as amendments to the certificate of incorporation and annual meeting voting results, provide insight into C4 Therapeutics capital structure and board-level decisions.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the most important points in each filing, helping readers quickly understand topics like new clinical data disclosures, changes in collaboration arrangements, or the impact of financings on cash runway. Users interested in CCCC can consult this page to follow how C4 Therapeutics reports its clinical, financial and corporate developments through official SEC channels over time.
C4 Therapeutics (CCCC) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing a clinical-stage biopharmaceutical company advancing targeted protein degraders via its proprietary TORPEDO platform. The report highlights two clinical programs—cemsidomide (IKZF1/3) in multiple myeloma and CFT8919 (EGFR L858R) in NSCLC—and partnerships with Merck KGaA, Roche, Betta Pharma, Pfizer, and Biogen. Management reports net losses of $105.0M in 2025 and $105.3M in 2024, a market value of $100.05M for non-affiliate equity as of June 30, 2025, and 97,578,175 shares outstanding as of February 23, 2026. The filing outlines R&D strategy, collaboration payments and milestones, intellectual property positions, manufacturing reliance on CMOs, and regulatory pathways for oncology and CNS programs.
C4 Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on four items: electing three Class III directors, an advisory vote on executive pay, ratifying KPMG as auditor, and amending the 2020 Stock Option and Incentive Plan’s evergreen provision to count pre-funded warrants.
The proxy highlights 2025 progress, including advancing lead degrader cemsidomide into Phase 2 and Phase 1b multiple myeloma studies, launching a new discovery strategy in inflammation, neuroinflammation and neurodegeneration, and deepening collaborations with Biogen, Merck KGaA and Roche. The company also raised $125 million in an underwritten offering, extending its cash runway to the end of 2028.
C4 Therapeutics Inc Schedule 13G/A amendment shows Wasatch Advisors beneficially owned 4,581,761 shares of common stock, representing 4.7% of the class as reported. The filing lists sole voting and sole dispositive power over the same 4,581,761 shares. Signature date is 04/22/2026.
C4 Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s second amended and restated by-laws on April 9, 2026. The change designates the U.S. District Courts for the District of Massachusetts and the District of Delaware as the exclusive forums for resolving federal securities law claims, unless the company agrees in writing to another forum.
The amendment covers actions arising under the Securities Act of 1933, the Securities Exchange Act of 1934, and related rules and regulations. The Board adopted this forum selection provision in response to recent amendments to Delaware corporate law. The full text of the by-laws amendment is filed as an exhibit.
C4 Therapeutics, Inc. entered into a major research collaboration and license agreement with Roche to discover, develop and commercialize degrader‑antibody conjugates (DACs) for oncology. C4T grants Roche a worldwide, exclusive license for DACs against two undisclosed cancer targets, while Roche funds all development, regulatory, manufacturing and commercialization activities.
C4T will receive a $20.0 million upfront cash payment and is eligible for over $1.0 billion in development, regulatory and commercial milestone payments, plus tiered royalties ranging from mid‑single digit to low‑double digit percent on net sales. Roche also holds an option, for an additional fee, to add a third oncology target with its own milestones and royalties. The agreement can be terminated for customary reasons, and Roche may also terminate for convenience with 90 days’ notice.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Kenneth Carl Anderson received a grant of 4,259 shares of common stock of C4 Therapeutics, Inc. as compensation for his services as a non-employee director, in lieu of cash fees. The grant was valued at $2.70 per share, based on the closing market price on April 1, 2026. Following this award, he holds 68,230 shares directly, and additional shares are held indirectly through several irrevocable and revocable trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received 5,370 shares of common stock as compensation. The shares were issued under the company’s Non-Employee Director Compensation Policy, where she elected stock instead of cash fees for board service.
The value was based on the closing market price of $2.70 per share on April 1, 2026. After this grant, she directly holds 71,512 shares of C4 Therapeutics common stock.
CCCC submitted a Form 144 notice for the proposed sale of 101,175 shares of common stock via a stock option exercise to be effected on 03/09/2026. The filing also records a prior sale of 11,517 shares on 02/17/2026 with proceeds shown as $21,193.82.
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, using its proprietary TORPEDO platform to design small‑molecule degraders. Its lead programs are cemsidomide for multiple myeloma and CFT8919 for EGFR L858R‑mutant non‑small cell lung cancer, both orally bioavailable oncology candidates.
The company is extending its pipeline into inflammation, neuroinflammation and neurodegeneration, including CNS‑penetrant degraders. It relies heavily on third‑party manufacturers and strategic collaborations with Roche, Biogen, Merck KGaA, Betta Pharma and Pfizer. C4 reported net losses of $105.0 million in 2025 and $105.3 million in 2024 and expects to incur losses for several years, requiring substantial additional funding.
C4 Therapeutics reported fourth quarter and full-year 2025 results and outlined progress across its pipeline. Total revenue was $11.0 million for Q4 and $35.9 million for 2025, roughly flat year over year, while operating expenses declined modestly.
Full-year R&D was $104.2 million and G&A was $36.2 million, contributing to a net loss of $105.0 million, or $1.27 per share. Cash, cash equivalents and marketable securities were $297.1 million as of December 31, 2025, and the company expects this to fund its operating plan to the end of 2028. Strategically, cemsidomide advanced into a Phase 2 trial in later-line multiple myeloma, a Phase 1b combination study with elranatamab is expected to start in Q2 2026, C4T earned a $2 million milestone from Biogen for BTK degrader BIIB145, and it raised $125 million in an October 2025 equity offering.